Please login to the form below
PD-L1/ PD-1 inhibitor
This page shows the latest PD-L1/ PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor ... class. The molecule is designed to simultaneously target two
Latest news
-
Tecentriq misses the mark in advanced ovarian cancer
PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The FDA approval for Imfinzi makes AZ’s
-
AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq
The green light makes Imfinzi (durvalumab) the first PD-1/PD-L1 inhibitor to challenge Roche’s Tecentriq (atezolizumab) in ES-SCLC, which became the first checkpoint inhibitor to be approved ... In ES-SCLC, additional heavyweight competition could be
-
BMS scores first oesophageal cancer nod for Opdivo in Japan
The approval in oesophageal cancer is particularly important for BMS as it continues to fight for its place in the PD-1/L1 inhibitor class, while Merck &Co’s Keytruda (pembrolizumab) ... The MHLW approved Opdivo based on the results from the phase 3
-
FDA sets June decision date for Tecentriq monotherapy in NSCLC
Tecentriq also beat chemotherapy in terms of patients who experienced grade 3-4 treatment-related adverse events, with 12.9% of people treated with the PD-L1 inhibitor experiencing one compared ... However, the NSCLC therapy area is dominated by
-
Merck chases Roche with triple-negative breast cancer data for Keytruda
Data demonstrated a delay in disease progression or death. Merck &Co/MSD has chalked up a clinical trial win for its PD-1 inhibitor Keytruda in triple-negative breast cancer that ... Keytruda is the top-selling PD-1/PD-L1 inhibitor worldwide thanks to
More from news
Approximately 1 fully matching, plus 59 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- A creative awakening – how pharma is bringing innovation to the patient journey
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- The pharma dichotomy
- Our Top 5 Pharma Picks From Cannes Lions
- Live Webinar: Streamlining the Drug Development Process to Transform Global Health
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Pfizer, Mylan move ahead with generics merger and spin-out
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- Roche shares new positive Ocrevus data for MS patients
PMHub
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
